Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Sym-023 by Les Laboratoires Servier for Metastatic Bile Duct Cancer: Likelihood of Approval
Sym-023 is under clinical development by Les Laboratoires Servier and currently in Phase I for Metastatic Bile Duct Cancer. According...
Sym-023 by Les Laboratoires Servier for Non-Small Cell Lung Cancer: Likelihood of Approval
Sym-023 is under clinical development by Les Laboratoires Servier and currently in Phase II for Non-Small Cell Lung Cancer. According...
Sym-023 by Les Laboratoires Servier for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
Sym-023 is under clinical development by Les Laboratoires Servier and currently in Phase I for Esophageal Squamous Cell Carcinoma (ESCC)....
Sym-023 by Les Laboratoires Servier for Metastatic Biliary Tract Cancer: Likelihood of Approval
Sym-023 is under clinical development by Les Laboratoires Servier and currently in Phase I for Metastatic Biliary Tract Cancer. According...
Sym-023 by Les Laboratoires Servier for Extrahepatic Bile Duct Cancer: Likelihood of Approval
Sym-023 is under clinical development by Les Laboratoires Servier and currently in Phase I for Extrahepatic Bile Duct Cancer. According...
Sym-023 by Les Laboratoires Servier for Gallbladder Cancer: Likelihood of Approval
Sym-023 is under clinical development by Les Laboratoires Servier and currently in Phase I for Gallbladder Cancer. According to GlobalData,...
Sym-023 by Les Laboratoires Servier for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Sym-023 is under clinical development by Les Laboratoires Servier and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According...
Sym-023 by Les Laboratoires Servier for Solid Tumor: Likelihood of Approval
Sym-023 is under clinical development by Les Laboratoires Servier and currently in Phase I for Solid Tumor. According to GlobalData,...